Role of Cryptic Activation Site within B1 Integrins in Breast Tumor Growth
Recent studies suggest that a group of molecules call Integrins play critical roles in breast cancer and some work has suggested that they may actually reduce the effectiveness of certain types of chemotherapy. Our laboratory has generated an antibody that only recognizes an activated form of these molecules. The unique characteristics of this new antibody (FM155) allow us the opportunity to target these Integrins in a highly selective manner. Thus, we have proposed to evaluate the effects of combining FM155 with chemotherapy to examine whether this unique strategy may enhance the effectiveness of existing therapy for the treatment breast cancer.